Company intelligence / Profile preview

Animol Discovery

Boston, Massachusetts, United Statesanimol-discovery.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Animol Discovery leverages a proprietary technology platform that integrates DNA encoded libraries with advanced AI/machine learning and computational chemistry to accelerate the discovery of innovative small molecule pharmaceuticals for animal health. The company focuses on unmet needs in both companion and production animals, targeting parasitic infections and chronic conditions. Backed by leading life sciences investors, Animol has raised significant capital to expand its pipeline but has not yet reported late-stage or commercialized assets.

Therapeutic areas: OtherInfectious Diseases
Modalities: Small molecules
Industry: Veterinary

Beyond the preview

Go deeper on Animol Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Animol Discovery.

Explore the full profile